Literature DB >> 20219620

Extrarenal manifestations of autosomal dominant polycystic kidney disease.

Yves Pirson1.   

Abstract

Although asymptomatic in most patients, extrarenal manifestations of ADPKD may become more clinically relevant with the increasing life expectancy of affected patients. They mainly encompass cysts in other organs than the kidney (liver: 94%, seminal vesicle: 40%, pancreas: 9%, arachnoid membrane: 8%, and spinal meningeal, 2%) and connective tissue abnormalities (mitral valve prolapse: 25%, intracranial aneurysms: 8%, and abdominal hernia: 10%). Their recognition may spare the patient from other, useless investigations (eg, when an arachnoid cyst is incidentally found) or lead to the implementation of prophylactic or therapeutic measures (eg, screening, sometimes followed by the treatment of an asymptomatic intracranial aneurysm in at-risk patients, or, in the presence of a severe polycystic liver disease, avoidance from estrogens and treatment aimed to slow cyst growth). 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20219620     DOI: 10.1053/j.ackd.2010.01.003

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  44 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

3.  The relationship between liver cyst volume and QOL in Japanese ADPKD patients.

Authors:  Satoru Muto; Masahiko Ando; Saori Nishio; Kazushige Hanaoka; Yoshifumi Ubara; Ichiei Narita; Kouichi Kamura; Toshio Mochizuki; Ken Tsuchiya; Kazuhiko Tsuruya; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2019-12-26       Impact factor: 2.801

4.  Polycystin signaling is required for directed endothelial cell migration and lymphatic development.

Authors:  Patricia Outeda; David L Huso; Steven A Fisher; Marc K Halushka; Hyunho Kim; Feng Qian; Gregory G Germino; Terry Watnick
Journal:  Cell Rep       Date:  2014-04-24       Impact factor: 9.423

5.  Adult patients with sporadic polycystic kidney disease: the importance of screening for mutations in the PKD1 and PKD2 genes.

Authors:  Hartmut P H Neumann; Janina Bacher; Zinaida Nabulsi; Nadine Ortiz Brüchle; Michael M Hoffmann; Elke Schaeffner; Jens Nürnberger; Markus Cybulla; Jochen Wilpert; Peter Riegler; Robert Corradini; Annette Kraemer-Guth; Pablo Azurmendi; Mercedes Nunez; Sven Gläsker; Klaus Zerres; Cordula Jilg
Journal:  Int Urol Nephrol       Date:  2012-02-25       Impact factor: 2.370

Review 6.  Evaluation of hepatic cystic lesions.

Authors:  Marten A Lantinga; Tom J G Gevers; Joost P H Drenth
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

7.  Surgery for diverticular disease results in a higher hernia rate compared to colorectal cancer: a population-based study from Ontario, Canada.

Authors:  E S Tang; D I Robertson; M Whitehead; J Xu; S F Hall
Journal:  Hernia       Date:  2017-11-16       Impact factor: 4.739

8.  The risk factors and the impact of hernia development on technique survival in peritoneal dialysis patients: a population-based cohort study.

Authors:  Shang-Feng Yang; Chia-Jen Liu; Wu-Chang Yang; Chao-Fu Chang; Chih-Yu Yang; Szu-Yuan Li; Chih-Ching Lin
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 9.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

Review 10.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.